Services
Biologic Therapeutics Development
Antibody & Protein Discovery
Target Discovery & Validation
Antibody Discovery
Antibody & Protein Production
Preclinical Testing
Structure & Biochemical Characterization
Preclinical Testing Bioassays & Immunoassays
Efficacy Models
Antibody & Protein Pharmacology
Antibody & Protein Toxicology
In Vitro
ADME
Biologics Testing
CDMO
Cell Line Development
Cell Banking
Analytical & Bioassay Quality Control
Pharmaceutical Stability Analysis
Lot Release Testing
cGMP Manufacturing
IND Regulatory
Co-Development Program by Targets
Next-IO™ T Cell related Therapeutics
Next-IO™ Anti-FGL1 Monoclonal Antibody Program
Next-IO™ Anti-FGL2 Monoclonal Antibody Program
Next-IO™ Anti-Siglec-15 Monoclonal Antibody Program
Next-IO™ Anti-TIM3 Monoclonal Antibody Program
Next-IO™ Anti-4-1BB Monoclonal Antibody Program
Next-IO™ Anti-CD19 × CD28 Bispecific Antibody Program
Next-IO™ Anti-CD27 Monoclonal Antibody Program
Next-IO™ Anti-CD40L Monoclonal Antibody Program
Next-IO™ Anti-GITR Monoclonal Antibody Program
Next-IO™ Anti-ICOS Monoclonal Antibody Program
Next-IO™ Anti-TMIGD2 Monoclonal Antibody Program
Next-IO™ Anti-HVEM/TNFRSF14 Monoclonal Antibody Program
Next-IO™ Anti-VISTA Monoclonal Antibody Program
Next-IO™ Anti-PD1 × TIM3 Bispecific Antibody Program
Next-IO™ Anti-TIGIT Monoclonal Antibody Program
Next-IO™ Anti-BTLA Monoclonal Antibody Program
Next-IO™ Anti-CD160 Monoclonal Antibody Program
Next-IO™ Anti-CTLA-4 × CD40 Combination Antibody Program
Next-IO™ Anti-PD-L1 × CD28 Bispecific Antibody Program
Next-IO™ Anti-ROR1 × CD28 Bispecific Antibody Program
Next-IO™ Anti-CD20 × CD28 Bispecific Antibody Program
Next-IO™ Anti-CD226 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-CD96 Therapeutic Monoclonal Antibody Program
Next-IO™ ICOS × PD-1 Therapeutic Bispecific Antibody Program
Next-IO™ NK Cell related Therapeutics
Next-IO™ Fusion Proteins of NKG2D Program
Next-IO™ Anti-sMIC Monoclonal Antibody Program
Next-IO™ Anti-CD48 Monoclonal Antibody Program
Next-IO™ Anti-2B4 Monoclonal Antibody Program
Next-IO™ Anti-HLA-G Monoclonal Antibody Program
Next-IO™ Anti-KIR2DL4 Monoclonal Antibody Program
Next-IO™ Anti-KIR2DL1-3 Monoclonal Antibody Program
Next-IO™ Anti-CD94/NKG2A Monoclonal Antibody Program
Next-IO™ Anti-PVR Monoclonal Antibody Program
Next-IO™ Anti-CD96 Monoclonal Antibody Program
Next-IO™ Anti-CD16 IgG Program
Next-IO™ Anti-LILRB1 Monoclonal Antibody Program
Next-IO™ Anti-KLRG1 Monoclonal Antibody Program
Next-IO™ Anti-Cadherin Monoclonal Antibody Program
Next-IO™ Anti-LLT1 Monoclonal Antibody Program
Next-IO™ Anti-NKRP1A Monoclonal Antibody Program
Next-IO™ Targeting Sialic Acid Program
Next-IO™ Anti-Nectin-2 Monoclonal Antibody Program
Next-IO™ Tumor Associated Antigens
Next-IO™ Anti-CD73 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-GPVI Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-Phosphatidylserine Monoclonal Antibody Program
Next-IO™ Anti-CD47 Therapeutic Monoclonal Antibody Program
Next-IO™ CD47 × PD-L1 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-Ang2 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-BCMA × CD3 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-CD123 × CD3 Therapeutic Bispecific Antibody Program
Next-IO™ CD47 × PD-L1 Dual-Targeted Therapeutic Fusion Protein Program
Next-IO™ CD47 × CD19 Therapeutic Bispecific Antibody Program
Next-IO™ CD47 × MSLN Therapeutic Bispecific Antibody Program
Next-IO™ CD47 × EGFR Dual-Targeted Therapeutic Fusion Protein Program
Next-IO™ TGF-β × PD-L1 Bi-Functional Therapeutic Fusion Protein Program
Next-IO™ Anti-GPC3 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-GPC3 × CD3 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-GPA33 × CD3 Bispecific DART Protein Program
Next-IO™ Anti-GPRC5D × CD3 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-GPC3 Therapeutic CAR-T Cell Program
Next-IO™ Anti-GPC3 Therapeutic CAR-NK Cell Program
Next-IO™ Anti-MUC16 × CD3 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-CDH3 × CD3 Bispecific DART Protein Program
Next-IO™ Anti-PSMA × CD3 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-SSTR2 × CD3 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-MSLN Therapeutic Fusion Protein Program
Next-IO™ Anti-MSLN × CD3 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-CD47 × PD-L1 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-CD47 × CD20 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-PD-L1 × 4-1BB Therapeutic Bispecific Antibody Program
Next-IO™ Anti-PD-L1 × 4-1BB Therapeutic Bispecific DART Program
Next-IO™ Anti-CD24 Monoclonal Antibody Program
Next-IO™ PD-L1 × TIM-3 Therapeutic Bispecific Antibody Program
Next-IO™ PD-1 × CTLA-4 Therapeutic Bispecific Antibody Program
Next-IO™ PSCA × CD3 Therapeutic Bispecific Antibody Program
Next-IO™ 4-1BB × PD-L1 Therapeutic Bispecific Antibody Program
Next-IO™ A2AR Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-Galectin-3 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-GPC3 Therapeutic Vaccine Program
Next-IO™ Anti-LAG-3 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-YTHDF1 Therapeutic Monoclonal Antibody Program
Next-IO™ c-MET × CTLA-4 Therapeutic Bispecific Antibody Program
Next-IO™ CD22 × CD19 Therapeutic CAR-T Program
Next-IO™ CD22 Therapeutic CAR-T Program
Next-IO™ CTLA-4 × OX40 Therapeutic Bispecific Antibody Program
Next-IO™ GITR × CTLA-4 Therapeutic Bispecific Antibody Program
Next-IO™ HER2 × HER3 Therapeutic Bispecific Antibody Program
Next-IO™ HER3 Therapeutic Monoclonal Antibody Program
Next-IO™ LAG-3 × PD-L1 Therapeutic Bispecific Antibody Program
Next-IO™ LAG-3 × CTLA-4 Therapeutic Bispecific Antibody Program
Next-IO™ LGR5 Therapeutic Monoclonal Antibody Program
Next-IO™ MHC I:LILRB2 Axis Therapeutic Monoclonal Antibody Program
Next-IO™ PAUF Therapeutic Monoclonal Antibody Program
Next-IO™ Chemokines & Chemokine Receptors-Related Therapeutics
Next-IO™ Anti-CCL2/CCR2 Axis Targeted Therapeutic Antibody Program
COVID-19 Recovered Patient-Derived Anti-SARS-CoV-2 Therapeutic Antibody Development
Next-IO™ Alzheimer's Disease Therapeutics
Next-IO™ Macrophages-related Therapeutics
Integrated Solutions for Cancer Immunotherapy Development
Products
Oncology Cell Lines
Cancer Cell Lines
Reporter Cell Lines
Luciferase Cell Lines
EGFP Cell Lines
Dual Labeled Cell Lines
Gene Editing Cell Lines
KO Cell Lines
Knockin Cell Lines
Knockdown Cell Lines
Primary Cells
Stem Cells
Drug Resistant Cells
OncoImmune Cells
Oncology Kits
Consumables
Tumor Marker Kits
Oncology Assay Tools
Metabolomics Analysis Tools
Animal Models
Synthetic Gene Circuit Cells
Cell Transport Capsule Kits
ADME
Absorption
Distribution
Metabolism
Excretion
Collaborations
Company
About Us
Contact
Careers
Events
Service
Product
Search
Home
Products
Oncology Cell Lines
PharmaOnco™ SKOV-3-FLuc-GFP Reporter Cell Line
Inquiry
Datasheet
CAT#:
ITS-0523-LX39
Product Type:
Reporter Cell Line
Organism:
Human
Overview
Short Description
PharmaOnco™ SKOV-3-FLuc-GFP Reporter Cell Line (ITS-0523-LX39) is a luciferase and GFP-labeled cell line used in cancer research.
Features
Dual labeled with luciferase and fluorescent reporters
Applications
in vitro
assay;
in vivo
imaging
Organism
Human
Strain Name
SKOV-3-FLuc-GFP
Tissue
Ovary; Ascites
Disease
Adenocarcinoma
Morphology
Epithelial-like
Biosafety Level
BSL-2
Specification
Oncology Cell Line
SKOV-3
Luciferase Classification
Firefly Luciferase
Quantity
>1 million cell/vial
Unit Size
2 vials
Culture Properties
Adherent
Cell Viability
>80%
Sterility Testing
Sterility testing in accordance with USP and EP regulations.
Identity Testing
STR identification
Mycoplasma Testing
Negative
Shipping
Dry Ice
Storage
Frozen cells should be stored in a liquid nitrogen tank.
Warnings
Avoid multiple freeze/thaw cycles
Related Products
PharmaOnco™ Mouse YUMM1.7 Tumor Cell Line
(CAT#: IOC-ZP280)
PharmaOnco™ HEK293T-Tg(Human Gαqi5//Human MT2 Receptor) Stable Cell Line, Single Clone
(CAT#: ITS-0624-HMM274)
PharmaOnco™ Jurkat-TCR KO Cell Line, Single Clone
(CAT#: ITS-0822-HMM207)
PharmaOnco™ HEK293T-Tg(Human DP2 Receptor) Stable Cell Line, Single Clone
(CAT#: ITS-0624-HMM399)
PharmaOnco™ HEK293T-Tg(Human kappa Receptor) Stable Cell Line, Single Clone
(CAT#: ITS-0624-HMM339)
PharmaOnco™ HEK293T-Tg(Human CCR3 Receptor) Stable Cell Line, Single Clone
(CAT#: ITS-0624-HMM90)
PharmaOnco™ Human Hep G2 Tumor Cell Line
(CAT#: IOC-ZP142)
PharmaOnco™ HEK293T-Tg(Rat EP2 Receptor) Stable Cell Line, Single Clone
(CAT#: ITS-0624-HMM403)
For Research Use Only | Not For Clinical Use
Online Inquiry
Send